دورية أكاديمية
أعرض في EDS

Riparin-B as a Potential Inhibitor of AdeABC Efflux System from Acinetobacter baumannii .

التفاصيل البيبلوغرافية
العنوان: Riparin-B as a Potential Inhibitor of AdeABC Efflux System from Acinetobacter baumannii .
المؤلفون: Leão PVS; Laboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, Piauí, Brazil., Ferreira ALDS; Laboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, Piauí, Brazil., Oliveira FAA; Laboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, Piauí, Brazil., Mesquita ABS; Laboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, Piauí, Brazil., Lima-Net JS; Department of Pharmacy, Federal University of Piauí, Teresina, Piauí, Brazil., Gutierrez SJC; Department of Pharmacy, Federal University of Piauí, Teresina, Piauí, Brazil., Nogueira CES; Department of Biological Chemistry, Regional-University of Cariri, Crato, Ceará, Brazil., Cruz-Martins N; Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, Porto 4200-319, Portugal.; Institute for Research and Innovation in Health (i3S), University of Porto, Porto 4200-135, Portugal., Arcanjo DDR; Laboratory of Functional and Molecular Studies on Physiopharmacology (LAFMOL), Department of Biophysics and Physiology, Federal University of Piaui, Teresina, Piauí, Brazil., Barreto HM; Laboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, Piauí, Brazil., Lima Ferreira JH; Laboratory of Research in Microbiology, Department of Parasitology and Microbiology, Federal University of Piaui, Teresina, Piauí, Brazil.
المصدر: Evidence-based complementary and alternative medicine : eCAM [Evid Based Complement Alternat Med] 2023 Apr 08; Vol. 2023, pp. 1780838. Date of Electronic Publication: 2023 Apr 08 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub Country of Publication: United States NLM ID: 101215021 Publication Model: eCollection Cited Medium: Print ISSN: 1741-427X (Print) Linking ISSN: 1741427X NLM ISO Abbreviation: Evid Based Complement Alternat Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2011- : New York, NY : Hindawi Pub.
Original Publication: Oxford, UK : Oxford University Press, c2004-
مستخلص: Acinetobacter baumannii is an important opportunistic pathogen that causes serious health-related infections, especially in intensive care units. The present study aimed to investigate the antimicrobial activity of Riparin-B (Rip-B) alone and in association with norfloxacin against multidrug-resistant clinical isolates of A. baumannii . For this, the minimum inhibitory concentrations were determined by the microdilution method. For the evaluation of resistance-modulating activity, MIC values for antibiotics were determined in the presence or absence of subinhibitory concentrations of Rip-B or chlorpromazine (CPZ). The AdeABC-AdeRS efflux system genes from these isolates were detected by PCR. Docking studies were also carried out to evaluate the interaction of Riparin-B and the AdeABC-AdeRS efflux system. The study was conducted from 2017 to 2019. The results showed that Rip-B showed weak intrinsic activity against the strains tested. On the other hand, Rip-B was able to modulate norfloxacin's response against A. baumannii strains that express efflux pump-mediated resistance. Docking studies provided projections of the interaction between Rip-B and EtBr with the AdeB protein, suggesting that Rip-B acts by competitive inhibition with the drug. Results found by in vitro and in silico assays suggest that Rip-B, in combination with norfloxacin, has the potential to treat infections caused by multidrug-resistant A. baumanni with efflux pump resistance.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2023 Patrícia Virna Sales Leão et al.)
References: J Clin Diagn Res. 2017 Feb;11(2):DC20-DC22. (PMID: 28384861)
Front Cell Infect Microbiol. 2017 Mar 13;7:55. (PMID: 28348979)
J Nat Sci Biol Med. 2016 Jan-Jun;7(1):58-61. (PMID: 27003971)
mBio. 2019 Jul 2;10(4):. (PMID: 31266873)
Exp Ther Med. 2017 May;13(5):2177-2182. (PMID: 28565825)
Jundishapur J Microbiol. 2014 Jan;7(1):e8691. (PMID: 25147654)
PLoS One. 2015 Jul 10;10(7):e0132843. (PMID: 26161744)
Int J Antimicrob Agents. 2016 Feb;47(2):107-16. (PMID: 26742726)
Indian J Med Res. 2018 Apr;147(4):413-421. (PMID: 29998878)
Microb Drug Resist. 2016 Jun;22(4):273-82. (PMID: 26745443)
J Antimicrob Chemother. 2006 May;57(5):970-4. (PMID: 16531429)
J Appl Microbiol. 2016 Nov;121(5):1312-1322. (PMID: 27537678)
J Antimicrob Chemother. 2014 Mar;69(3):632-6. (PMID: 24155060)
J Infect Public Health. 2018 Nov - Dec;11(6):812-816. (PMID: 29907439)
mBio. 2015 Mar 24;6(2):. (PMID: 25805730)
J Antimicrob Chemother. 2014 Mar;69(3):616-22. (PMID: 24150844)
Toxicol In Vitro. 2018 Aug;50:1-10. (PMID: 29476885)
J Ethnopharmacol. 2007 Apr 4;110(3):391-400. (PMID: 17317057)
Antimicrob Agents Chemother. 2013 Jul;57(7):2989-95. (PMID: 23587960)
Antimicrob Resist Infect Control. 2019 Nov 7;8:172. (PMID: 31719975)
BMC Complement Altern Med. 2017 Aug 14;17(1):405. (PMID: 28806947)
Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2141-7. (PMID: 24939621)
Antimicrob Agents Chemother. 2009 Sep;53(9):4045-7. (PMID: 19564367)
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21. (PMID: 20057044)
J Appl Microbiol. 1998 Apr;84(4):538-44. (PMID: 9633651)
Microbiol Res. 2016 Feb;183:60-7. (PMID: 26805619)
J Comput Chem. 2009 Dec;30(16):2785-91. (PMID: 19399780)
Antimicrob Agents Chemother. 1993 Jan;37(1):128-9. (PMID: 8431010)
Nucleic Acids Res. 2000 Jan 1;28(1):235-42. (PMID: 10592235)
J Nat Sci Biol Med. 2017 Jul-Dec;8(2):193-198. (PMID: 28781486)
Indian J Med Microbiol. 2015 Jan-Mar;33(1):87-91. (PMID: 25560008)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
Can J Microbiol. 2016 Sep;62(9):794-801. (PMID: 27332787)
Microb Pathog. 2019 May;130:242-246. (PMID: 30876871)
BMC Infect Dis. 2018 Dec 4;18(1):614. (PMID: 30509192)
Diagn Microbiol Infect Dis. 2016 May;85(1):90-7. (PMID: 26971181)
Drug Resist Updat. 2016 Jul;27:1-13. (PMID: 27449594)
Antimicrob Agents Chemother. 1999 Oct;43(10):2404-8. (PMID: 10508015)
PLoS One. 2012;7(11):e49534. (PMID: 23166700)
New Microbes New Infect. 2019 Apr 10;30:100549. (PMID: 31193498)
Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93. (PMID: 20014903)
Antimicrob Agents Chemother. 2003 Nov;47(11):3616-9. (PMID: 14576129)
تواريخ الأحداث: Date Created: 20230424 Latest Revision: 20230425
رمز التحديث: 20230425
مُعرف محوري في PubMed: PMC10118900
DOI: 10.1155/2023/1780838
PMID: 37089710
قاعدة البيانات: MEDLINE
الوصف
تدمد:1741-427X
DOI:10.1155/2023/1780838